Home › Compare › REBL vs MRK

REBL vs MRK: Dividend Comparison 2026

REBL yields 6666.67% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 REBL wins by $1028095347812062.00M in total portfolio value
10 years
REBL
REBL
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full REBL calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — REBL vs MRK

📍 REBL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodREBLMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, REBL + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
REBL pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REBL
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, REBL beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REBL + MRK for your $10,000?

REBL: 50%MRK: 50%
100% MRK50/50100% REBL
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

REBL
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REBL buys
0
MRK buys
0
No recent congressional trades found for REBL or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricREBLMRK
Forward yield6666.67% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$1028095347812062.00M ✓$56.8K
Annual income after 10y$998,628,545,336,266,700,000.00 ✓$9,798.13
Total dividends collected$1026118102492338.88M ✓$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: REBL vs MRK ($10,000, DRIP)

YearREBL PortfolioREBL Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$677,367$666,666.67$11,206$366.19+$666.2K → REBL
2$42,928,313$42,203,530.63$12,650$502.35+$42.92M → REBL
3$2,545,616,701$2,499,683,405.64$14,407$694.19+$2545.60M → REBL
4$141,255,910,403$138,532,100,533.89$16,585$967.82+$141255.89M → REBL
5$7,335,374,338,812$7,184,230,514,680.15$19,342$1,363.89+$7335374.32M → REBL
6$356,516,885,536,661$348,668,034,994,132.70$22,913$1,947.19+$356516885.51M → REBL
7$16,218,956,689,966,618$15,837,483,622,442,392.00$27,662$2,823.89+$16218956689.94M → REBL
8$690,711,023,145,868,900$673,356,739,487,604,600.00$34,159$4,173.35+$690711023145.83M → REBL
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$43,337$6,308.80+$27539067734387.93M → REBL
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$56,776$9,798.13+$1028095347812062.00M → REBL

REBL vs MRK: Complete Analysis 2026

REBL — Stock

Rebel Group Inc., through its subsidiaries, organizes, promotes, and hosts mixed martial arts (MMA) events in China and Singapore. It also produces and distributes videos of its MMA events, through the Internet and social media, as well as sells the rights to such videos to distribute to television stations. The company is headquartered in Xuhui, China.

Full REBL Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this REBL vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REBL vs SCHDREBL vs JEPIREBL vs OREBL vs KOREBL vs MAINREBL vs JNJREBL vs ABBVREBL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.